Ropes & Gray advisedĀ Ginkgo Bioworks, a horizontal platform for cell programming, in an agreement to acquire biotechnology company Zymergen in an all-stock transaction that values Zymergen at approximately $300 million.
Under the agreement, which has been unanimously approved by the board of directors of both companies, Zymergen stockholders will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each Zymergen share, representing a 5.25% pro forma ownership of Ginkgo following the transaction that wasĀ announcedĀ on July 25.
The Ropes & Gray team was led by mergers & acquisitions partnerĀ Suni Sreepada, mergers & acquisitions associateĀ Kate FisherĀ and mergers & acquisitions partnerĀ Marko ZatylnyĀ and included IP transactions partnerĀ Amanda Austin, employment & benefits partnersĀ Renata Ferrari,Ā Richard KiddĀ andĀ Megan Bisk, tax partnerĀ Pam Glazier, litigation & enforcement partnersĀ Lisa Bebchick,Ā Mike McFalls,Ā Martin Crisp,Ā Ama AdamsĀ andĀ Ruchit Patel, life sciences regulatory & compliance partnerĀ Kellie Combs, real estate partnerĀ Peter Alpert, data, privacy & cybersecurity partnerĀ Ed McNicholas, IP transactions partnerĀ Melissa Rones, business restructuring partnerĀ Andrew Devore, private equity partnerĀ Milap Patel, health care counselĀ Leslie Thornton, life sciences regulatory & compliance counselĀ Beth Weinman, litigation & enforcement counselĀ Deidre Johnson,Ā Alison McLaughlinĀ andĀ Joseph Rafferty, real estate counselĀ Laurie NelsonĀ and private equity counselĀ James Kaplan.
